Phaseline

Companies › Zynerba Pharmaceuticals

Zynerba Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Other.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ZYN002
Cannabidiol transdermal gel
CNR1, CNR2Phase 2Fragile X Syndrome–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03802799ZYN002Phase 2Fragile X SyndromeOtherJun 2026

Targets

CNR1 (1) CNR2 (1)

Companies with the same targets

IGC Pharma Bazelet Nehushtan Incannex Healthcare Vertanical Alasht Pharmed Jazz Pharmaceuticals Sinfatin Skye Bioscience PleoPharma Laboratorio Elea Phoenix

Companies built like this

Vertanical Angitia Nocion Therapeutics Angitia Biopharmaceuticals Guangzhou Next Life Sciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.